Sioux Pharm
Sioux Pharm Overview
The aggregated data is based on reviews and questionnaires provided by PissedConsumer.com users.
Sioux Pharm has 1.0 star rating based on 3 customer reviews. Consumers are mostly dissatisfied.
- Rating Distribution
Most users want Sioux Pharm to offer a solution to their issues.
Consumers are not pleased with Customer service and Discounts and Special Offers. The price level of this organization is high according to consumer reviews.
Media from reviews
This review is from a real person who provided valid contact information and hasn't been caught misusing, spamming or abusing our website. Check our FAQ
Verified Reviewer | Branchburg, New JerseySummit Nutritionals International Defeats Sioux Pharm, Inc. In Legal Battle
Summit Nutritionals International, Inc of New Jersey is victorious in their legal battle against Sioux Pharm, Inc of Sioux Center, Iowa. As of October 2, 2015, Dr. Allan Kramer, President of Sioux Pharm, Inc, has formally withdrawn all claims made against Summit Nutritionals International in Case No. LACV 023704 in the Distict Court in and for Woodbury County, Iowa.
In addition, Sioux Pharm retracts all allegations made against Summit Nutritionals International.
For more information regarding the recent victory of Summit Nutritionals against Sioux Pharm, please visit the following links.
https://youtu.be/3s2_LdrkHzE
https://www.youtube.com/watch?v=HiNmCtBkvOc
https://drive.google.com/open?id=0Bw_vbILKB2esbXRYMnJfT0dQOTA
http://summitnutritionals.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/
http://summitnutritionals.net/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/
http://americanchondroitin.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/
http://usachondroitin.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/
http://summitnutritionalsinc.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/
http://droi-kon.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/
http://sioux-pharm-inc-and-sioux-pharm-biochemical.pissedconsumer.com/summit-nutritionals-vs-sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-201510****3890.html
http://www.scam.com/showthread.php?685246-Summit-Nutritionals-International-vs-Sioux-Pharm-Inc-Withdrawal-of-Claims-and-Retraction-of-Allegations&p=188****#post188****
https://summitnutritionals.wordpress.com
Preferred solution: Let the company propose a solution
This review is from a real person who provided valid contact information and hasn't been caught misusing, spamming or abusing our website. Check our FAQ
Verified ReviewerSummit Nutritionals vs. Sioux Pharm, Inc. - Sioux Center, Iowa
Exmo. Senhor Juiz
do Tribunal da Comarca de Lisboa
SUMMIT NUTRITIONALS INTERNATIONAL INC., sucursal em Portugal, com
o NPC 98041****, com domicilio em Lisboa, no Empreendimento Nova
Amoreiras – Palácio- 3ºpiso, secção 9, Rua Artilharia Um, 71-77, 125*-038
Lisboa, Portugal,
Vem requerer contra,
SIOUX PHARM INC., sociedade comercial norte americana com sede em
121 19th Street SW
Sioux Center, IA 51250, Iowa, Estados Unidos da América,
PROVIDÊNCIA CAUTELAR NÃO ESPECIFICADA, nos termos e com os
fundamentos seguintes:
1
A Reqte, SUMMIT NUTRITIONALS INTERNATIONAL INC., é uma sociedade comercial, com sede em New
Jersey, EUA, que, através da sua sucursal em Portugal, se dedica à comercialização, nos países da União
Europeia, de sulfato de condroitina, sob a marca DROI-KON, que importa dos EUA.
2
O produto comercializado pela Reqte, SUMMIT NUTRITIONALS INTERNATIONAL INC., é sulfato de condroitina
do grau alimentar, em que é requisito de pureza que tenha um teor de sulfato de condroitina em percentagem
não inferior a 90%, existindo também no mercado o sulfato de condroitina do grau farmacêutico que, além do
mesmo teor mínimo de sulfato de condroitina, deve ainda satisfazer determinados requisitos da USP
(Farmacopeia dos E.U.A.), conforme se elucida na informação de que se junta cópia como doc. nº1 e aqui se dá
por reproduzida.
3
A Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., adquire habitualmente o produto que comercializa
ao fabricante EAGLE LABORATORIES INC., cuja fábrica se situa no Estado de IOWA nos E.U.A.
4
A Reqda., SIOUX PHARM INC., é uma sociedade comercial com sede no dito Estado de IOWA, que se dedica à
fabricação e comercialização de sulfato de condroitina de grau farmacêutico, sob a marca CHONDROPURE,
entre outros produtos.
5
O sulfato de condroitina do grau alimentar é comercializado na Europa por um preço entre vinte e trinta Euro por
kilo, enquanto o preço do de grau farmacêutico excede os cem Euro por kilo.
6
O produto comercializado pela Reqte. SUMMIT NUTRITIONALS INTERNATIONAL INC., é por esta submetido a
análises em laboratórios acreditados pela FDA - Food and Drug Administration dos E.U.A. (o seu próprio
laboratório e 4 laboratórios independentes), tendo sempre tais análises evidenciado a existência nas amostras
de, pelo menos, 90% de sulfato de condroitina, ou seja, o grau de pureza exigido para o produto. Juntam-se,
como exemplos, certificado de análises e relatórios das 5 análises referidas nesse certificado, como docs. nºs. 2
a 7, que aqui se dão por reproduzidos.
7
Os clientes da Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., que, na Europa, são mais de duas
dezenas, procedem também a análises de amostras do produto fornecido pela Reqte., SUMMIT NUTRITIONALS
INTERNATIONAL INC., em laboratórios de sua escolha, e até à presente data não apresentaram qualquer
reclamação por falta de pureza do produto, antes se manifestaram sempre inteiramente satisfeitos com a
qualidade do produto fornecido pela Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC.
8
Importa relevar que a Reqte., SUMMIT NUTRITIONALS INTERNATIONAL, INC., obteve do muito exigente
Better Business Bureau Serving New Jersey a acreditação como empresa que adopta práticas de negócio
conformes com a ética na publicidade, nas vendas e nas relações com os clientes, como resulta do certificado
de que se junta cópia como doc. nº 8 e aqui se dá por reproduzido.
9
Importa referir que os métodos de análise adequados ao produto de grau alimentar são diferentes dos
adequados ao produto de grau farmacêutico, podendo estes últimos, se usados em análises de amostras de
produto do grau alimentar, conduzir a resultados de pureza inferior à exigida.
10
No âmbito de uma disputa industrial e comercial com a referida fornecedora da Reqte., SUMMIT
NUTRITIONALS INTERNATIONAL INC., a Reqda., SIOUX PHARM INC., instaurou no Tribunal de IOWA uma
acção em que denuncia actos de espionagem industrial e de adulteração do sulfato de condroitina por adição de
maltodextrina, cometidos pela EAGLE LABORATORIES INC.
11
Em termos manifestamente abusivos, uma vez que a Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC.,
como a Reqda., SIOUX PHARM INC., perfeitamente sabe, não é fabricante e se limita a comercializar o produto
que adquire a fabricantes, a Reqda., SIOUX PHARM INC., alega nessa acção que também a Reqte., SUMMIT
NUTRITIONALS INTERNATIONAL INC., e uma outra empresa Cliente da Eagle Laboratories procederiam à
referida diluição do sulfato de condroitina com maltodextrina.
12
A Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., não tem razões para admitir que a sua fornecedora
EAGLE LABORATORIES INC. proceda a adulterações do produto, mas pode assegurar que, ainda que tenha
tais comportamentos, não existe qualquer adulteração no produto que é fornecido à Reqte., SUMMIT
NUTRITIONALS INTERNATIONAL INC., como resulta das análises a que, sistematicamente, tanto a Reqte.,
SUMMIT NUTRITIONALS INTERNATIONAL INC., como os seus clientes, procedem.
13
No falso pressuposto de que a Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., comercializa o produto
adulterado, para mais contribuindo para tal adulteração, a Reqda., SIOUX PHARM INC., acusa a Reqte.,
SUMMIT NUTRITIONALS INTERNATIONAL INC., da inerente concorrência desleal e pede que a Reqte,
SUMMIT NUTRITIONALS INTERNATIONAL INC., seja condenada no pagamento de indemnização dos danos
sofridos pela Reqda., SIOUX PHARM INC., que não especifica nem quantifica, bem como que seja intimada a
não diluir e a não distribuir ou vender sulfato de condroitina diluído e, em manifesto excesso face aos factos
alegados, que a Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., tenha a sua actividade concorrente
com a da Reqda., SIOUX PHARM INC., paralisada ou suspensa durante, no mínimo, a pendência da acção.
14
Este último pedido da Reqda., SIOUX PHARM INC., serve bem a ilustrar o seu objectivo real de aceder a uma
posição monopolista ou quase monopolista no mercado do produto em causa, reduzido ao de grau farmacêutico,
que um pedido que fosse meramente corolário dos factos alegados, ou seja, o da intimação da Reqte, SUMMIT
NUTRITIONALS INTERNATIONAL INC., à não comercialização de produto adulterado, não lhe permitiria
alcançar.
15
Tendo em conta que a Reqda, SIOUX PHARM INC., comercializa também o seu produto na U.E., a Reqte.,
SUMMIT NUTRITIONALS INTERNATIONAL INC., receia fundadamente que a Reqda., SIOUX PHARM INC.,
que igualmente tem Clientes nesse mercado, em comportamentos de concorrência contrários às normas e usos
honestos de qualquer ramo da actividade económica, tente também perturbar a actividade da sucursal em
Portugal da Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., seja através de falsas afirmações com o
fim de a desacreditar, seja através de falsas descrições sobre a qualidade do produto comercializado pela Reqte.
SUMMIT NUTRITIONALS INTERNATIONAL INC..
16
Tendo em conta a grande diferença de preço entre o produto comercializado pela Reqda., SIOUX PHARM INC.,
e o produto comercializado pela Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., bem se compreende
o interesse da Reqda., SIOUX PHARM INC., em desacreditar ou mesmo eliminar do mercado empresas que
fornecem um segmento do mercado com produto de preço muito mais baixo, cujos clientes só recorrerão à
compra do produto, de grau farmacêutico, da Reqda., SIOUX PHARM INC., quando estiverem em causa
utilizações ou exigências dos clientes finais que não possam de todo ser satisfeitas com o produto de grau
alimentar.
17
Mas a Reqda., SIOUX PHARM INC., não se fica por estes comportamentos de concorrência desleal, que já usou
na acção instaurada no IOWA, antes, na sua ganância, trata também de adulterar o seu próprio produto,
procurando assim aumentar os seus ganhos também por redução dos custos de fabrico.
18
A adulteração do produto da Reqda., SIOUX PHARM INC., que só a esta pode imputar-se, pôde ser constatada
pela Reqte. SUMMIT NUTRITIONALS INTERNATIONAL INC., através da análise do conteúdo de uma
embalagem perfeitamente identificada como de Chondropure, fornecido pela Reqda., SIOUX PHARM INC.
19
Essa embalagem, tal como foi fornecida pela Reqda., SIOUX PHARM INC., a uma empresa que é também
Cliente da Reqte. SUMMIT NUTRITIONALS INTERNATIONAL INC., do produto de grau alimentar, foi colocada
por essa empresa à disposição da Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., para análise.
20
Da análise, efectuada por um laboratório independente aprovado pela FDA, resultou que o produto fornecido
pela Reqda., SIOUX PHARM INC., nem sequer satisfaz os requisitos do grau alimentar, pois apresenta um teor
de sulfato de condroitina de apenas 24,90%, não satisfazendo igualmente outros requisitos do grau
farmacêutico, como resulta do relatório da análise datado de 4.3.2015 e da identificação da amostra analisada,
que se juntam como docs. nºs. 9 e 10 e aqui se dão por reproduzidos.
21
Ao comercializar o produto com tais desconformidades em relação às características que deveria ter em
correspondência com as expectativas dos Clientes e com o anunciado pela Reqda., SIOUX PHARM INC., esta
incorre, também por isso, em concorrência desleal, por falsa descrição ou indicação sobre a qualidade e a
utilidade do produto.
22
A Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., tem o direito de exercer a sua actividade económica
lícita e transparente, no mercado Europeu, em leal concorrência com outros operadores nesse mercado e
protegida de perturbações causadas por operadores que actuem ao arrepio das honestas práticas dessa
actividade.
23
Os comportamentos estigmatizados da Reqda., SIOUX PHARM INC., fazem recear a Reqte. SUMMIT
NUTRITIONALS INTERNATIONAL INC., que aquela venha a utilizá-los para interferir e perturbar ilicitamente a
sua actividade no mercado Europeu.
24
Este receio da Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., encontra sólido fundamento naqueles
comportamentos da Reqda., SIOUX PHARM INC., e é de molde a justificar plenamente as providências
concretamente adequadas a assegurar a efectividade do direito ameaçado da Reqte, SUMMIT NUTRITIONALS
INTERNATIONAL INC..
25
Tais providências são, neste caso, a intimação da Reqda., SIOUX PHARM INC., para que se abstenha de toda e
qualquer afirmação susceptível de desacreditar a Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., e o
seu produto e, bem assim, se abstenha de introduzir no mercado Europeu sulfato de condroitina que não
satisfaça inteiramente o requisito de pureza de um teor de, pelo menos, 90% deste produto e, tratando-se de
sulfato de condroitina do grau farmacêutico, que não satisfaça os demais requisitos exigidos para esse grau do
produto.
26
O risco de lesão que se pretende acautelar é o de a Reqda., SIOUX PHARM INC., vir a causar dano irreparável
ou de muito difícil reparação à Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., por afectação da sua
reputação de honestidade, e ao seu produto, por dúvidas sobre a sua pureza, com inevitáveis reflexos junto da
clientela da Reqte., SUMMIT NUTRITIONALS INTERNATIONAL INC., susceptível de conduzir a uma drástica
redução do seu nível de vendas com substituição por concorrentes que, posteriormente, será muito difícil, se não
impossível, desalojar.
27
Tal risco não é especialmente prevenido por nenhuma das providências legalmente tipificadas.
28
Cumpre ainda mencionar que, face ao previsível comportamento da Reqda., SIOUX PHARM INC., o não
decretamento da presente providência cautelar importará para a ora Reqte., SUMMIT NUTRITIONALS
INTERNATIONAL INC., que sempre tem pautado o seu comportamento pela transparência, rigor e cumprimento
das normas e usos honestos do ramo da actividade económica em que se insere, incomensuráveis prejuízos,
potenciando a redução do seu nível de vendas e prejudicando a sua credibilidade no mercado.
29
Por outro lado, do decretamento da providência requerida, que não será mais do que exigir da Reqda., SIOUX PHARM INC.,
que actue de acordo com as honestas práticas da actividade exercida, designadamente abstendose
de adulterar o produto comercializado, nenhum prejuízo poderá obviamente resultar para a Reqda., SIOUX PHARM INC..
Nestes termos e nos mais de direito aplicáveis,
deverá a Reqda., SIOUX PHARM INC., ser
intimada para que se abstenha de toda e qualquer
afirmação susceptível de desacreditar a Reqte.,
SUMMIT NUTRITIONALS INTERNATIONAL INC.
e o seu produto e, bem assim, se abstenha de
introduzir no mercado Europeu Sulfato de
condroitina que não satisfaça inteiramente o
requisito de pureza de um teor de, pelo menos,
90% deste produto e, tratando-se de sulfato de
condroitina do grau farmacêutico, que não
satisfaça os demais requisitos exigidos para esse
grau do produto.
Para tanto, requer a V. Exa. mande proceder à
citação da Reqda., nos termos da Convenção de
Haia de 15 de Novembro de 1965 (formulário
junto), para, querendo, deduzir oposição, no prazo
e sob a cominação legal, seguindo-se o demais
termos até final.
Esta providência é requerida como preliminar de acção de condenação da Reqda. SIOUX PHARM INC., nos
mesmos termos do pedido ora formulado, de cuja propositura a Reqte., SUMMIT NUTRITIONALS
INTERNATIONAL INC., desde já requer dispensa no pressuposto de a matéria a adquirir neste procedimento
permitir formar convicção segura acerca da existência do direito acautelado, sendo a providência a decretar
adequada a realizar a composição definitiva do litígio.
Google Docs
https://drive.google.com/file/d/0BxwrutfOyLhCTG42SE1aV1VncDg/view?usp=sharing
https://drive.google.com/file/d/0BxwrutfOyLhCOWtjV0NfZjhhNUE/view?usp=sharing
https://drive.google.com/file/d/0BxwrutfOyLhCNzlyRFNfRG10T2c/view?usp=sharing
https://drive.google.com/file/d/0BxwrutfOyLhCamtXNG1MZE5HXzQ/view?usp=sharing
https://drive.google.com/file/d/0BxwrutfOyLhCbmhJODJMUFpMY1k/view?usp=sharing
Preferred solution: Let the company propose a solution
This review is from a real person who provided valid contact information and hasn't been caught misusing, spamming or abusing our website. Check our FAQ
Verified ReviewerSummit Nutritionals International vs. Sioux Pharm,Inc. - Sioux Falls, IA
To The Honorable Judge of
the Lisbon District Court
SUMMIT NUTRITIONAL INTERNATIONAL
INC., branch in Portugal, Juristic Person
Number 98041****, with its domicile in
Lisbon, at Empreendimento Nova
Amoreiras – Palácio- 3ºpiso, secção 9, Rua
Artilharia 1, 71-77, 125*-038 Lisboa,
Portugal
Hereby commences non-typified interlocutory
injunction proceedings against,
SIOUX PHARM INC., an American company
with its registered office in 121 19th Street SW
Sioux Center, IA 51250, Iowa, United States of America
in the following terms and on the following
grounds,
1
The Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., is a
commercial company, with its registered office in New Jersey, USA, which, via
its branch in Portugal, is in the business of the commercialization in the
European Union of chondroitine sulphate with the brand name DROI-KON,
which it imports from the USA.
2
The product commercialized by the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., is food grade chondroitine sulphate, which is subject to
a purity requirement that it must contain not less than 90% of chondroitine
sulphate. There is also pharmaceutical grade chondroitine sulphate on the
market, which must not only have the same minimum chondroitine sulphate
content, but is also required to comply with certain requirements of the USP
(USA Pharmacopeia). As clarified in the information attached as document no.1.
which contents are incorporated by this reference.
3
The Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., habitually
acquires the product it commercializes from the manufacturer EAGLE
LABORATORIES INC., whose plant is located in the State of IOWA in the USA.
4
The Respondent, SIOUX PHARM INC., is a commercial company with its
registered office in the said state of IOWA, which is in the business of the
manufacture and commercialization of pharmaceutical grade chondroitine
sulphate under the CHONDROPURE brand name, among other products.
5
Food grade chondroitine sulphate is commercialized in Europe at a price
between twenty and thirty euro/kilo, while the price of the pharmaceutical grade
product is more than one hundred euro/kilo.
6
The product commercialized by the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., is submitted by it for analysis by laboratories accredited
by the FDA - Food and Drug Administration in the USA, and these analyses
have always shown the existence of at least 90% of chondroitine sulphate in the
samples, i.e., the product’s required purity level. Certificate of analysis, and
reports of 5 analysis referred in this certificate, are attached as document no.2
to 7, which contents are incorporated by this reference.
7
The Applicant’s clients in Europe, of which there are more than twenty, also
conduct analyses of samples of the product supplied by the Applicant SUMMIT
NUTRITIONALS INTERNATIONAL INC., at laboratories selected by them. As at
the date hereof, none of the said clients have complained regarding the purity of
the product and they have always expressed their total satisfaction with the
quality of the product supplied by the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC.
8
It is important to highlight that the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., acquired from the extremely demanding “Better
Business Bureau Serving New Jersey”, the accreditation as a company that
uses business practices according to ethics in advertisement, in sales and in
commercial relationships with clients, as displayed in the certificate attached as
document no.8, which contents are incorporated by this reference.
9
It is noteworthy that the methods of analysis appropriate to the analysis of the
food grade product differ from those appropriate to the analysis of the
pharmaceutical grade product. Furthermore, if analysis methods appropriate to
the analysis of the pharmaceutical grade product are used to analyze the food
grade product, the results obtained can show a purity level which is less than
the required level.
10
In an industrial and commercial dispute with the Applicant's said supplier, the
Respondent, SIOUX PHARM INC., commenced legal proceedings in IOWA in
which it complains of acts of industrial espionage and of the adulteration of
chondroitine sulphate by EAGLE LABORATORIES INC., via the addition of
maltodextrin.
11
The Respondent, SIOUX PHARM INC., also claims in the said legal
proceedings that the Applicant, SUMMIT NUTRITIONALS INTERNATIONAL
INC., and another company, which is also a client of Eagle Laboratories,
together with latter have diluted chondroitine sulphate with maltodextrin. This
claim is manifestly untrue as the Respondent, SIOUX PHARM INC., is well
aware that the Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., is
not a manufacturer and that it merely commercializes the product it acquires
from manufacturers.
12
The Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., has no
reason to believe that its supplier EAGLE LABORATORIES INC. adulterates
the product, but can assert that even if its said supplier is guilty of the said
conduct, there is no adulteration of the product supplied to the Applicant,
SUMMIT NUTRITIONALS INTERNATIONAL INC., as is clear from the analyses
systematically carried out by both the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., and its clients.
13
On the false assumption that the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., commercialized an adulterated product and that it has
contributed to the said adulteration, the Respondent, SIOUX PHARM INC.,
accuses the Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., of
unfair competition and seeks that damages be awarded against the Applicant,
SUMMIT NUTRITIONALS INTERNATIONAL INC., with regard to the loss and
damage suffered by the Respondent, SIOUX PHARM INC., which loss and
damage it neither specifies not quantifies, and that the Applicant, SUMMIT
NUTRITIONALS INTERNATIONAL INC., be freezed from diluting chondroitine
sulphate and from distributing or selling diluted chondroitine sulphate, and
further that the Applicant’s business in competition with the Respondent, SIOUX PHARM INC., be restrained or suspended at least while the proceedings are
pending, which latter claim is manifestly excessive in the light of the facts
pleaded.
14
The Respondent’s latter claim is a clear illustration of its real objective, which is
to achieve a monopoly, or quasi-monopoly, in the market for the product in
question, reduced to pharmaceutical grade, which is something that a remedy,
which is merely corollary to the facts pleaded, i.e. that the Applicant, SUMMIT
NUTRITIONALS INTERNATIONAL INC., be restrained from commercializing
the adulterated product, would not permit it to achieve.
15
Given the fact that the Respondent, SIOUX PHARM INC., also commercializes
its product in the EU, the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., has good reason to fear that the Respondent, SIOUX PHARM INC., which also has clients in this market, will seek to perturb the
activity of the Applicant’s branch in Portugal, via false statements intended to
discredit it, i.e. false descriptions of the quality of the product commercialized by
the Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., which
amounts to anti-competitive conduct that is contrary to the honest custom and
practice in any economic activity.
16
Given the great difference between the price of the product commercialized by
the Respondent, SIOUX PHARM INC., and the product commercialized by the
Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., it is easy to
comprehend the Respondent’s, SIOUX PHARM INC., interest in discrediting the
Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., or even in
eliminating companies from the market that supply a market segment with a
much lower prices, which will only have recourse to the Respondent’s, SIOUX PHARM INC., product, when the uses of the product or the requirements of the
end clients cannot at all be satisfied by the food grade product.
17
Furthermore, the Respondent’s, SIOUX PHARM INC., conduct is not limited to
this unfair competition, to which it has already had recourse in the legal
proceedings in IOWA. The Respondent’s, SIOUX PHARM INC., greed is such
that it adulterates its own product in order to increase its profits, not only by
increasing its sales through the elimination of the Applicant, SUMMIT
NUTRITIONALS INTERNATIONAL INC., from the market but also by reducing
its production costs by adulteration of the product.
18
The adulteration of the Respondent’s, SIOUX PHARM INC., product, for which
only the Respondent, SIOUX PHARM INC., can be responsible, was noted by
the Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., via an
analysis of the contents of a package clearly identified as Chondropure,
supplied by the Respondent, SIOUX PHARM INC..
19
This package was supplied by the Respondent, SIOUX PHARM INC., to a
company that is also a food grade client of the Applicant, SUMMIT
NUTRITIONALS INTERNATIONAL INC., and was made available by the said
company for analysis by the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC.
20
The analysis of the said product by an independent laboratory approved by the
FDA, showed that the product supplied by the Respondent, SIOUX PHARM INC., does not even comply with the requirements applicable to the food grade
product, as the chondroitine content of the product was only 24.90% and also
does not comply with other requirements applicable to the pharmaceutical
grade product, as result from the analysis report from the 4th March 2015, and
from the identification of the analyzed sample, which are attached as
documents no. 9 and no. 10 which contents are incorporated by reference.
21
By selling the said non-compliant product that lacks the required characteristics
and does not meet the expectations of the Respondent’s, SIOUX PHARM INC.,
clients and lacks the characteristics announced by the Respondent, SIOUX PHARM INC., it is also guilty of unfair competition on the grounds of false
description or incorrect indication of the product’s quality and use.
22
The Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., is entitled to
carry on its lawful and transparent economic activity in the European market in
fair competition with the other operators in this market and to be protected from
perturbations caused by operators that act in violation of the honest practices of
this business.
23
The Respondent’s, SIOUX PHARM INC., stigmatized conduct causes the
Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., to fear that it will
apply them in order to wrongfully interfere with and perturb its business in the
European market.
24
The Applicant’s fear is amply justified by the Respondent’s, SIOUX PHARM INC., said conduct and fully justifies the grant of appropriate interlocutory
injunctions in order to protect the Applicant’s threatened right.
25
In this case, the interlocutory injunctions sought are that the Respondent,
SIOUX PHARM INC., be restrained from making any statements likely to
discredit the Applicant, SUMMIT NUTRITIONALS INTERNATIONAL INC., and
its product and that it be further restrained from introducing chondroitine
sulphate into the European market that does not comply fully with the purity
requirement of at least 90% of this product and that, in the case of
pharmaceutical grade chondroitine sulphate, which does not comply with the
other requirements applicable to that grade of product.
26
The risk of harm that the Applicant, SUMMIT NUTRITIONALS
INTERNATIONAL INC., seeks to prevent is the risk that the Respondent,
SIOUX PHARM INC., will cause irreparable harm, or harm that is difficult to
remedy, to it, by affecting its reputation for honesty and the reputation of its
product, by raising doubts as to the purity thereof, and that this will have an
inevitable effect on the Applicant’s clients and is likely to result in a drastic
reduction of its sales and in its replacement by competitors, which it would
subsequently be difficult, if not impossible, to dislodge.
27
The said risk is not specifically provided for in any of the interlocutory injunctions
typified in the law.
28
It is important to refer, due to the predictable behavior of the Respondent,
SIOUX PHARM INC., not granting the protective order, matters to the Applicant,
SUMMIT NUTRITIONALS INTERNATIONAL INC, who has always showed in its
behavior transparency, strictness and the following the rules and honest
practices of the branch of the commercial activity they are inserted, enormous
damages, leading to a sales reduction and damaging its credibility in the market.
29
On another hand, from the granting of the protective order, which will not be
more than demanding from the Respondent, SIOUX PHARM INC., acts
accordingly to the honest practices of the practiced activity, mainly by avoiding
the adulteration of the commercialized product, no damage, obviously can result
to the Respondent, SIOUX PHARM INC.
Accordingly and on such other
grounds as this Honorable Court
finds on its own motion, the
Respondent, SIOUX PHARM INC.,
should be restrained from
making any statements likely to
discredit the Applicant, SUMMIT
NUTRITIONALS
INTERNATIONAL INC., and its
product and be further restrained
from introducing Chondroitine
Sulphate into the European
market that does not comply fully
with the purity requirement of at
least 90% of this product and, in
the case of pharmaceutical
grade chondroitine sulphate,
which does not comply with the
other requirements applicable to
that grade of product.
The Applicant requests that this
petition is served to the
Defendant in the terms of the
Hague Convention 15 November
1965 in order for the Defendant
to oppose to this petition within
the legal delay.
This protective order is requested as a preliminary to the action of
condemnation of the Respondent, SIOUX PHARM INC; in the same terms
requested in this petition.
Evidence:
Witness: Ana Santos, married, manager, with address at Empreendimento Nova
Amoreiras, Palácio – 3º Piso/Secção 9 Rua Artilharia 1, 71-77, 125*-038
Lisboa, Portugal
The attorney
Henrique Abecasis
Preferred solution: Let the company propose a solution
Companies Similar to Sioux Pharm
Thank You for Your Reply! We are processing your message.
Your comment is successfully posted.
Summit Nutritionals International, Inc of New Jersey is victorious in their legal battle against Sioux Pharm, Inc of Sioux Center, Iowa. As of October 2, 2015, Dr.
Allan Kramer, President of Sioux Pharm, Inc, has formally withdrawn all claims made against Summit Nutritionals International in Case No. LACV 023704 in the Distict Court in and for Woodbury County, Iowa.
In addition, Sioux Pharm retracts all allegations made against Summit Nutritionals International.
For more information regarding the recent victory of Summit Nutritionals against Sioux Pharm, please visit the following links.
https://youtu.be/3s2_LdrkHzE
https://www.youtube.com/watch?v=HiNmCtBkvOc
https://drive.google.com/open?id=0Bw_vbILKB2esbXRYMnJfT0dQOTA http://summitnutritionals.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/ http://summitnutritionals.net/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/ http://americanchondroitin.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/ http://usachondroitin.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/ http://summitnutritionalsinc.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/ http://droi-kon.com/sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-against-summit-nutritionals-international-inc/ http://sioux-pharm-inc-and-sioux-pharm-biochemical.pissedconsumer.com/summit-nutritionals-vs-sioux-pharm-inc-withdrawal-of-claims-and-retraction-of-allegations-201510****3890.html http://www.scam.com/showthread.php?685246-Summit-Nutritionals-International-vs-Sioux-Pharm-Inc-Withdrawal-of-Claims-and-Retraction-of-Allegations&p=188****#post188**** https://summitnutritionals.wordpress.com